What the FDA labels say about taking them together
Insulin human and octreotide
Insulin human's FDA label of March 7, 2025 names octreotide in its drug interactions section; the octreotide labels PlainMeds reads (4) do not name insulin human. The insulin human label: “… Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as …”
Check it at the source: the insulin human FDA label on DailyMed (effective March 7, 2025, Baxter Healthcare Corporation); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the insulin human label say about octreotide?
Insulin human label, drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.
Afrezza label (Mannkind Corporation, May 30, 2026), drug interactionsClinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs.
Source: FDA drug label (Afrezza, BLA022472), Mannkind Corporation, effective May 30, 2026 (SPL set 29f4637b-e204-425b-b89c-7238008d8c10), via openFDA
Source: FDA drug label (MYXREDLIN), Baxter Healthcare Corporation, effective March 7, 2025 (SPL set afca6e80-a802-49fb-a978-5fe28a173001), via openFDA; the full label on DailyMed
What does the octreotide label say about insulin human?
Octreotide's label (effective July 22, 2026) and its 3 other brand-application labels do not name insulin human in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin human | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $4.26 per mL 70-30 vial | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once